explore -WSS

explore

author：comprehensive 2025-10-03 00:40:16 - browse：712

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The simple reason for the increase in autism diagnosis

WSS

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Wegovy leads to weight loss. Can it treat depression, too?

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Investment in vaccine development is lagging, report finds

explore

explore

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Investment in vaccine development is lagging, report finds

As demand for Covid shots wanes, Moderna seeks its next success

Boston competes with Raleigh

Virginia high school admissions case could be legal follow

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Tori Bowie and the unacceptable rates of Black maternal death

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Biogen walks away from Aduhelm, years after polarizing approval

Wikipedia

10 reasons why health care startups fail

The sun may be out, but guns are not. A lawsuit challenges a new gun ban on Hawaii beaches

Why Medicare shouldn’t cover every FDA

Illumina to lay off 10% of research and development team

How generative AI ratchets up security threats for health systems

Supreme Court strikes down Biden student loan forgiveness program

focus

focus

focus

knowledge